In 2020, the company experienced a 4% increase in net sales to $19.1 billion, driven by increased demand in the Consumer Tissue segment and an organic sales growth of 6%. Adjusted gross margin improved by 210 basis points to 37.1%, resulting in a $575 million cost savings from restructuring programs. Adjusted operating margin also increased by 90 basis points, contributing to an adjusted earnings per share of $7.74, a 12% rise from the previous year. Cash provided by operations reached a record $3.7 billion, bolstered by strong working capital performance. For 2021, the company anticipates total sales growth of 4% to 6%, with organic sales growth of 1% to 2%. Adjusted earnings per share are projected to be between $7.75 and $8.00, nearly matching 2020 levels.